To test whether IL-17 shapes the tumor promoting effects of MSCs, we established melanoma model through the administration of B16F0 tumor cells together with cytokine-pretreated MSCs, and then compared the effect of MSCs with or without IL-17 on tumor growth. This evidence concerns the gene IL17A and melanoma.